Larry Alphs

7.5k total citations · 2 hit papers
174 papers, 5.2k citations indexed

About

Larry Alphs is a scholar working on Psychiatry and Mental health, Clinical Psychology and Philosophy. According to data from OpenAlex, Larry Alphs has authored 174 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 129 papers in Psychiatry and Mental health, 37 papers in Clinical Psychology and 31 papers in Philosophy. Recurrent topics in Larry Alphs's work include Schizophrenia research and treatment (113 papers), Mental Health and Psychiatry (31 papers) and Bipolar Disorder and Treatment (30 papers). Larry Alphs is often cited by papers focused on Schizophrenia research and treatment (113 papers), Mental Health and Psychiatry (31 papers) and Bipolar Disorder and Treatment (30 papers). Larry Alphs collaborates with scholars based in United States, Belgium and Canada. Larry Alphs's co-authors include William T. Carpenter, Robert W. Buchanan, Brian Kirkpatrick, Douglas W Heinrichs, John Panagides, Jun Zhao, Cynthia A. Bossie, Dong‐Jing Fu, Ibrahim Turkoz and Roger S. McIntyre and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and American Journal of Psychiatry.

In The Last Decade

Larry Alphs

172 papers receiving 5.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The schedule for the deficit syndrome: An instrument for research in schizophrenia

1989 629 citations Larry Alphs et al. Psychiatry Research profile →
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study

2018 357 citations Carla M. Canuso, Jaskaran Singh et al. profile →

Peers

Countries citing papers authored by Larry Alphs

Since Specialization

Citations

This map shows the geographic impact of Larry Alphs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Larry Alphs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Larry Alphs more than expected).

Fields of papers citing papers by Larry Alphs

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Larry Alphs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Larry Alphs. The network helps show where Larry Alphs may publish in the future.

Co-authorship network of co-authors of Larry Alphs

This figure shows the co-authorship network connecting the top 25 collaborators of Larry Alphs. A scholar is included among the top collaborators of Larry Alphs based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Larry Alphs. Larry Alphs is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Revealing heterogeneity in chronic lymphocytic leukemia: AI-driven insights into aggressive and indolent disease subtypes. 2024 ·Journal of Clinical Oncology ·Bessi Qorri, Joseph Geraci, (unknown), Christian Cumbaa, Larry Alphs, Luca Pani	1
2	Using Machine Learning to Explore Multimodal Digital Markers for Early Detection of Cognitive Impairment in Alzheimer’s Disease 2024 ·Alzheimer s & Dementia ·Joseph Geraci, (unknown), Bessi Qorri, (unknown), (unknown), (unknown), Katherine A. Gifford, Abhishek Pratap, Mike J. Tsay, Christian Cumbaa, Luca Pani, Larry Alphs, Rhoda Au	1
3	Earlier Use of Long-Acting Injectable Paliperidone Palmitate Versus Oral Antipsychotics in Patients With Schizophrenia 2023 ·The Journal of Clinical Psychiatry ·(unknown), Larry Alphs, Martha Sajatovic, Ibrahim Turkoz, Liping Sun, (unknown), Jennifer Kern Sliwa, Dean Najarian, H. Lynn Starr	2
4	Remote Assessment of Negative Symptoms of Schizophrenia 2023 ·Schizophrenia Bulletin Open ·David G. Daniel, Alex S. Cohen, Dawn I. Velligan, P.D. Harvey, Larry Alphs, Michael Davidson, William Z. Potter, (unknown), Nina R. Schooler, (unknown), Raeanne C. Moore, (unknown), Stephen R. Marder	5
5	Dispersion of cognitive performance test scores on the MATRICS Consensus Cognitive Battery: A different perspective 2022 ·Schizophrenia Research Cognition ·David J. Williamson, Keith H. Nuechterlein, Todd A. Tishler, Joseph Ventura, Benjamin M. Ellingson, Ibrahim Turkoz, Richard S.E. Keefe, Larry Alphs	2
6	Suicide Ideation and Behavior Assessment Tool (SIBAT): Evaluation of Intra- and Inter-Rater Reliability, Validity, and Mapping to Columbia Classification Algorithm of Suicide Assessment 2020 ·Psychiatry Research ·Larry Alphs, Dong‐Jing Fu, David J. Williamson, Ibrahim Turkoz, Carol Jamieson, Dennis A. Revicki, Carla M. Canuso	20
7	Clinical utility of the Negative Symptom Assessment-16 in individuals with schizophrenia 2019 ·European Neuropsychopharmacology ·Gurpreet Rekhi, Larry Alphs, (unknown), Jimmy Lee	10
8	An assessment of injection site reaction and injection site pain of 1-month and 3-month long-acting injectable formulations of paliperidone palmitate 2018 ·Perspectives In Psychiatric Care ·Jennifer Kern Sliwa, Adam Savitz, Isaac Nuamah, Maju Mathews, Srihari Gopal, Erica Elefant, Dean Najarian, Larry Alphs	11
9	A quantitative systems pharmacology study on optimal scenarios for switching to paliperidone palmitate once-monthly 2018 ·Schizophrenia Research ·Hugo Geerts, Äthan Spiros, Patrick J. Roberts, Larry Alphs	7
10	Assessment of Suicidal Ideation and Behavior 2017 ·The Journal of Clinical Psychiatry ·Phillip Chappell, Michelle Stewart, Larry Alphs, (unknown), Sarah Dubrava, Jill Harkavy‐Friedman, Pilar Lim, (unknown), Morton M. Silverman, Steven D. Targum, Stephen R. Marder	10
11	Cost effectiveness of paliperidone palmitate versus oral antipsychotics in patients with schizophrenia and a history of criminal justice involvement 2015 ·Journal of Medical Economics ·Erik Muser, Chris M Kozma, Carmela Benson, Lian Mao, H. Lynn Starr, Larry Alphs, John Fastenau	7
12	Negative Symptoms in Schizophrenia: An Update on Identification and Treatment 2014 ·The Psychiatric times ·Dawn I. Velligan, Larry Alphs	8
13	Onset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophrenia 2014 ·Expert Opinion on Pharmacotherapy ·Larry Alphs, Cynthia A. Bossie, Dong‐Jing Fu, (unknown), Jennifer Kern Sliwa	7
14	Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies 2013 ·Annals of General Psychiatry ·Michael A. Markowitz, Dong‐Jing Fu, Bennett Levitan, Srihari Gopal, Ibrahim Turkoz, Larry Alphs	28
15	Training for Assessment of Negative Symptoms of Schizophrenia across Languages and Cultures: Comparison of the NSA-16 with the PANSS Negative Subscale and Negative Symptom Factor 2011 ·Clinical Schizophrenia & Related Psychoses ·David G. Daniel, Larry Alphs, Pilar Cazorla, John J. Bartko, John Panagides	19
16	Are the Long-Acting Intramuscular Formulations of Risperidone or Paliperidone Palmitate Associated with Post-Injection Delirium/Sedation Syndrome? An Assessment of Safety Databases 2011 ·Current Drug Safety ·Larry Alphs, Srihari Gopal, Keith Karcher, Justine Kent, Jennifer Kern Sliwa, Stuart Kushner, Isaac Nuamah, Jaskaran Singh	15
17	Negative Symptoms in Schizophrenia: The Importance of Identification and Treatment 2008 ·The Psychiatric times ·Dawn I. Velligan, Larry Alphs	18
18	Transcultural differences in suicide attempters: Analysis on a high-risk population of patients with schizophrenia or schizoaffective disorder 2006 ·Schizophrenia Research ·A. Carlo Altamura, Emanuela Mundo, Roberta Bassetti, (unknown), J.P. Lindenmayer, Larry Alphs, Herbert Y. Meltzer	22
19	Comparison of withdrawal of typical and atypical antipsychotic drugs: a case study. 1991 ·PubMed ·Larry Alphs, (unknown)	23
20	Development of the Clozaril Patient Management System 1989 ·Psychopharmacology ·Bijan Bastani, Larry Alphs, Herbert Y. Meltzer	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact